Brinzolamide 1%,
does it really help with Lower intraocular pressure in open-angle glaucoma and ocular hypertension?
research showsBrinzolamide 1% ophthalmic suspension is rated B with 62 points because it significantly lowers intraocular pressure in open-angle glaucoma and ocular hypertension. In a randomized masked three-month trial of 463 participants, 1% brinzolamide twice or three times daily lowered pressure more than placebo, and an 18-month active-controlled trial of 378 participants maintained mean trough reductions of about 2.7 to 3.9 mm Hg. A meta-analysis of 28 randomized trials estimated relative peak and trough pressure reductions of about 17% for brinzolamide. Intraocular pressure is a validated therapeutic target for reducing glaucoma progression, but the brinzolamide trials did not directly test visual-field preservation as their primary long-term endpoint. The claimed pressure-lowering effect is therefore B, while brinzolamide-specific long-term visual preservation remains separately unproven.
ads claimFor a prescription eye drop, saying that it treats glaucoma can still be expanded into an implication that it restores lost vision or guarantees prevention of blindness. The direct evidence is pressure lowering; achievement of target pressure and preservation of the visual field and optic nerve require separate longitudinal monitoring and, when needed, combination or switching therapy.
Useful facts when choosing a product
- Brinzolamide 1% is a prescription ophthalmic suspension available as Azopt-associated and generic products. A common labeled regimen is one drop in the affected eye or eyes three times daily; shake well and follow the actual prescription.
- When another topical ophthalmic medicine is used, doses should be separated by at least ten minutes. Avoid touching the bottle tip to the eye, hand, or another surface to reduce contamination and infection risk.
- Blurred vision and bitter, sour, or unusual taste are common, and ocular irritation, pain, or dryness can occur. Soft contact lenses should be removed and reinserted at least 15 minutes after dosing because of the preservative.
- Brinzolamide is a sulfonamide with potential for serious hypersensitivity, and patients with low corneal endothelial cell counts need caution for corneal edema. It is not recommended in severe renal impairment, and additive systemic effects with oral carbonic anhydrase inhibitors or high-dose salicylates require review.
What the research actually shows
Sall 2000 randomized 463 adults with open-angle glaucoma or ocular hypertension to brinzolamide 1% twice or three times daily, dorzolamide, or placebo and evaluated three-month diurnal pressure; brinzolamide was superior to placebo. March 2000 followed 378 participants for 18 months and showed sustained pressure lowering with twice- and three-times-daily brinzolamide, although average reduction was smaller than with timolol. The 2005 van der Valk meta-analysis compared glaucoma medicines across 28 randomized trials and about 6,900 participants, estimating both peak and trough relative pressure reductions of 17% for brinzolamide. The Ocular Hypertension Treatment Study supports pressure lowering as a clinically validated target because topical therapy delayed glaucoma conversion, but it was not a brinzolamide-specific visual-field trial. Approval defines use; B reflects repeated direct pressure evidence together with the gap in long-term patient-centered outcomes.
Why this is classified as B (62)
A 463-participant placebo-controlled trial, a 378-participant 18-month active-controlled trial, and a 28-trial meta-analysis repeatedly demonstrated intraocular-pressure lowering with brinzolamide 1%. The meta-analysis estimated relative peak and trough reductions of about 17%, and the Ocular Hypertension Treatment Study validates pressure as a clinically meaningful treatment target, so the grade is not lowered to C. All brinzolamide trial endpoints were nevertheless pressure, product-specific long-term visual-field preservation is absent, and pivotal early evidence was concentrated in the manufacturer development program, supporting the bottom of B with 62 points. Ocular irritation, dysgeusia, sulfonamide hypersensitivity, and corneal edema are separate safety issues.
Counterpoint. If pressure remains above target or the visual field progresses, adherence and instillation technique should be checked and another class, laser, or surgery considered. A pressure reading alone does not prove treatment success.
Rejudgment record. Cross-check incorporated (editorial parity ruling) — Applied B because placebo-controlled and long-term active-controlled randomized trials and randomized-trial meta-analysis repeatedly demonstrated the claimed intraocular-pressure reduction and pressure is a validated treatment target, while brinzolamide-specific long-term visual-field preservation endpoints are absent and pivotal early studies were concentrated in the manufacturer development program
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Intraocular-pressure reduction with brinzolamide 1% in open-angle glaucoma | B | Direct pressure reduction was repeated in placebo-controlled, 18-month active-controlled, and meta-analytic evidence. |
| Intraocular-pressure reduction with brinzolamide 1% in ocular hypertension | B | Multiple randomized trials enrolling ocular-hypertension participants together with open-angle glaucoma showed significant pressure reduction versus placebo. |
| Long-term visual-field preservation specifically attributable to brinzolamide 1% | ? | Pressure lowering is a validated treatment target, but no long-term human efficacy trial directly testing visual-field preservation with brinzolamide alone was identified. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Sall K. 2000 | Multicenter randomized double- or triple-masked placebo- and active-controlled parallel trial | 409 | Alcon brinzolamide development program | Three-month diurnally corrected change in intraocular pressure | Brinzolamide 1% twice and three times daily lowered intraocular pressure significantly more than placebo and produced reductions similar to dorzolamide. | Core placebo-controlled randomized evidence for direct pressure lowering |
| March WF, Ochsner KI. 2000 | Eighteen-month multicenter randomized double-masked active-controlled trial | 75 | Manufacturer-development trial context | Eighteen-month trough intraocular pressure and safety | Twice- and three-times-daily brinzolamide maintained trough reductions of about 2.7 to 3.9 mm Hg, smaller than the 4.7-to-5.6-mm Hg reductions with timolol. | Supporting evidence for durability and comparative effect |
| van der Valk R et al. 2005 | Meta-analysis of randomized clinical trials of glaucoma medicines | 6,841 | Dutch Health Care Insurance Council | One-month peak and trough relative intraocular-pressure reduction | Brinzolamide was estimated to reduce intraocular pressure by about 17% from baseline at both peak and trough, versus about 5% with placebo. | Independent synthesis and effect-size evidence |
| Kass MA et al. 2002 OHTS | Randomized observation-controlled long-term treatment-strategy trial | 1,636 | Public support including the United States National Eye Institute | Five-year development of primary open-angle glaucoma through visual-field or optic-disc deterioration | Various topical pressure-lowering treatments reduced pressure by a mean of 22.5% and lowered five-year glaucoma development from 9.5% to 4.4%. | Clinical validation of the pressure target; not brinzolamide-specific evidence |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Brinzolamide 1% x lower intraocular pressure in open-angle glaucoma and ocular hypertension — Evidence Grade B·62. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/brinzolamide-one-percent-open-angle-glaucoma-ocular-hypertension-iop/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.